AUL
PTGX icon

AlphaGrep UK Ltd’s Protagonist Therapeutics PTGX Stock Holding History

AlphaGrep UK Ltd’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,070
Closed -$268K – 905
2025
Q4 		$268K Buy
+3,070
New +$251K 0.09% 492

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

AlphaGrep UK Ltd's PTGX Position: Q1 2026 in Review

AlphaGrep UK Ltd sold out of Protagonist Therapeutics (PTGX) in Q1 2026, closing a stake of 3,070 shares — an estimated $268K sold.

AlphaGrep UK Ltd first reported a position in PTGX in Q4 2025 and held it in 1 quarter. The position peaked at $268K in Q4 2025. 319 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • AlphaGrep UK Ltd reported no remaining Protagonist Therapeutics position as of Q1 2026 after selling out during the quarter.
  • AlphaGrep UK Ltd sold 3,070 Protagonist Therapeutics shares in Q1 2026, an estimated $268K.
  • AlphaGrep UK Ltd first reported a position in Protagonist Therapeutics in Q4 2025 and held it in 1 quarter.
  • AlphaGrep UK Ltd's Protagonist Therapeutics position peaked at $268K in Q4 2025.
  • 319 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on AlphaGrep UK Ltd's 13F filing for Q1 2026, filed 13 Aug 2026.